ClinicalTrials.gg
CompletedNCT06951009Updated Aug 17, 2026Results posted

Establishing Baseline Sysmex UF-5000 Flow Cytometer Results in Healthy Men

An interventional study of Colli-Pee and standard of care 60 mL urine cup in Urethritis and Healthy Men Age 18-50 With no Urethral Symptoms, sponsored by Indiana University. Completed at 1 site in United States. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Indiana University · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

Acute urethritis (inflammation of the male urethra) affects millions of men in the United States each year.

Effective management of STIs is complicated by asymptomatic infections, as men often delay seeking care until symptoms become severe. Yet, even men without symptoms can show measurable evidence of urethritis. Therefore, a cheap, simple, and non-invasive point-of-care (POC) test, providing results within 30 minutes, could significantly enhance STI management by facilitating early diagnosis and treatment.

A new diagnostic method, urine flow cytometry, has shown potential in hospital settings for accurately detecting inflammation by counting white blood cells (infection-fighting cells) in urine samples. The Sysmex UF-5000 flow cytometer, a state-of-the-art device, may offer a non-invasive, cost-effective, and accurate method to diagnose urethritis compared to traditional Gram stains and urinalysis, potentially extending its use beyond specialized clinics.

This study aims to determine the efficacy and precision of the Sysmex UF-5000 analyzer in diagnosing urethritis using first-catch urine samples. Additionally, the study seeks to evaluate whether urine collected using the 10 mL Colli-Pee device provides greater accuracy and precision compared to the standard urine cup (30-60 mL) when used with urine flow cytometry and LE urinalysis.

Read the detailed description

Acute urethritis (i.e., inflammation of the male urethra) affects millions of men within the United States annually. In young sexually active men, urethritis is most commonly caused by the sexually transmitted infections (STI) Neisseria gonorrhoeae (GC, causes gonorrhea) and Chlamydia trachomatis (CT, causes chlamydia), but can also be caused by a lengthening list of known and emerging pathogens that cause "nongonococcal urethritis" (NGU). STI management has proven challenging due to the prevalence of asymptomatic infections and because men often fail to seek STI care until they experience pronounced symptoms. However, even without urethral symptoms, most men with a urethral STI have measurable evidence of urethritis. Thus, a cheap, simple, and non-invasive point of care (POC) test (i.e., results available within 30 minutes) that accurately detects urethritis could be a game changer in STI management as asymptomatic infections could be detected and treated, potentially decreasing the risk of spreading STIs to sexual partners.

Currently, the only widely used POC test available for diagnosis of urethritis in men in the US is Gram stain microscopy of a urethral swab smear. This approach has been shown to be highly effective for identifying men who have urethritis and has 95% sensitivity for diagnosing GC in symptomatic men [4]. Although the urethral swab remains the gold standard test to diagnose urethritis at the POC, it is rarely used outside of specialized STI clinics given its many limitations, which include: (1) it often elicits severe pain, and in rare cases can permanently damage the urethra; (2) it requires specialized instrumentation (an inverted microscope with a 1000x objective) and Gram stain reagents; (3) it must also be administered and interpreted by trained personnel that have different inter-operator accuracy in reporting results, and (4) anxiety associated with this procedure is a common reason men cite for delaying STI care and failing to return for follow-up visits. In many other clinical settings, POC screening for STIs would be highly desirable, for example during annual wellness exams of high-risk male adolescents; screening with specific STI nucleic acid amplification tests (NAATs) is not cost-effective in low-risk populations and the urethral swab procedure is unacceptable in these populations. As an alternative approach, a few investigators have evaluated Leukocyte esterase (LE) testing as part of a routine urinalysis using first-catch urine to diagnose urethritis, but the low sensitivity and specificity of this approach has limited its use to resource-limited settings.

Flow cytometry is routinely used in clinical settings to identify populations of cells (e.g., neutrophils, red blood cells for whole blood counts) from blood and urine. Modern flow cytometers are highly automated, rapid, and inexpensive to run, which makes them an optimal assay for screening for urethritis by detecting elevated neutrophils in asymptomatic men. Interestingly, several recent publications have shown that flow cytometric analysis of urine can be used to diagnose urethritis with comparable sensitivity and specificity to the urethral Gram stain smear. However, most of these studies did not use state-of-the-art flow cytometers, did not calibrate Gram stain to flow cytometric results directly, and did not diagnose the sensitivity/specificity of this approach for detection of a broad section of urethral STI. The investigators hypothesize that the state-of-the-art flow cytometer analyzer, Sysmex UF-5000, may be able to similarly provide a non-invasive and cost-effective approach for urethritis diagnosis in men using first-catch urine when compared to Gram stain and urinalysis. A prior version, the Sysmex UF-1000i, has been shown to be promising in detection of urinary tract infections, but has not yet been studied in STIs. The UF-5000 could be a powerful screening approach for urethral STI that could be employed in a broad range of clinical settings, not just specialized STI clinics. Separately, if urine flow cytometry could be optimized to yield similar sensitivity to the Gram stain smear, the investigators suspect this approach would rapidly replace the Gram stain smear in clinical practice which in turn would improve patient capture and retention.

The investigators will recruit healthy men aged 18 to 50 who, after consenting to participate, will be assigned to start collecting a urine specimen three times week (typically, Monday, Wednesday, and Friday) for two weeks.

The device used to collect urine will be either a Colli-Pee or a standard-of-care 60 ml sterile urine cup. Participants with an odd birth year will use the Colli-Pee during the first week; even birth year participants will use the Colli-Pee during the second week.

02

Conditions studied

  • Urethritis
  • Healthy Men Age 18-50 With no Urethral Symptoms
03

In context

Lead sponsor

Indiana University is the lead sponsor of 991 studies on the registry; 202 are open to participants now.

Of its 150 completed or terminated interventional studies of FDA-regulated products, 118 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men aged 18 to 50.
  • No urethral symptoms (discharge, dysuria)

Exclusion criteria

Exclusion Criteria:

  • History of genital surgery or known urethral abnormalities
  • Testing positive for gonorrhea and chlamydia
  • Diagnosis of a sexually transmitted infection within the last year.
  • Not available to collect a urine specimen in the morning 3x/week for 2 weeks
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Colli-Pee collection followed by standard-of-care urine collection cup

    Participants with an odd birth year will collect urine using the Colli-Pee device during Week 1 and with the standard-of care urine cup during Week 2.

    Device: Colli-Pee · Device: standard of care 60 mL urine cup · Diagnostic Test: Urinalysis · Diagnostic Test: Sysmex UP-5000

  • Active comparator
    Standard-of-care urine collection followed by Colli-Pee collection

    Participants with an even birth year will collect urine using the standard-of-care urine cup during Week 1 and with the Colli-Pee device during Week 2.

    Device: Colli-Pee · Device: standard of care 60 mL urine cup · Diagnostic Test: Urinalysis · Diagnostic Test: Sysmex UP-5000

Interventions

  • DeviceColli-Pee

    The Colli-Pee device is a first void urine self-sampling device. Participants will collect urine samples with this device three times during one week of study participation. Urine sample collection with this device will occur either in Week 1 or Week 2 of study participation, depending on the Participant's Arm assignment.

  • Devicestandard of care 60 mL urine cup

    Participants will collect clean catch urine samples with this device three times during one week of study participation. Urine sample collection with this device will occur either in Week 1 or Week 2 of study participation, depending on the Participant's Arm assignment.

  • Diagnostic testUrinalysis

    Participant samples will be analyzed by urinalysis to evaluate for leukocyte esterase (LE).

  • Diagnostic testSysmex UP-5000

    Participant samples will be analyzed by the Sysmex UP-5000 to evaluate for white blood cells (WBCs) per microliter.

06

What researchers measure

Primary outcomes

  1. Median Urinary White Blood Cell Count (WBCs/uL) by Collection Device (Urine Cup vs Colli-Pee)

    Urinary white blood cell (WBC) counts (cells/µL) will be measured using a Sysmex UF-5000 urine flow cytometer. Each participant will provide urine samples on three separate days during each of two weeks, with samples collected using both a standard urine cup and a Colli-Pee device. WBC counts will be summarized using the median (and interquartile range) and compared between collection methods.

    Time frame: Monday, Wednesday, and Friday during Week 1 and Monday, Wednesday, and Friday during Week 2

  2. Proportion of Urine Samples Positive for Leukocyte Esterase (≥1+) by Collection Device (Urine Cup vs Colli-Pee)

    Urinary leukocyte esterase will be assessed by standard urinalysis (dipstick). Each participant will provide urine samples on three separate days during each of two weeks, with samples collected using both a standard urine cup and a Colli-Pee device. Leukocyte esterase results will be recorded as an ordinal categorical variable with levels: negative, 1+, 2+, 3+, and 4+, and compared between collection methods.

    Time frame: Monday, Wednesday, and Friday during Week 1 and Monday, Wednesday, and Friday during Week 2

  3. Within-Subject Coefficient of Variation of Urinary White Blood Cell Counts by Collection Device

    Participants will provide urine samples on three days during each week of participation, for a total of 2 weeks. Urine samples collected in standard-of-care urine cups and Colli-Pee devices will be compared for white blood cell (WBC) concentration (WBCs/µL), as measured by the Sysmex UF-5000. Day-to-day variability will be quantified as the within-subject coefficient of variation (CV%) across the three sample collections for each collection method. Results are summarized as the median (interquartile range) CV% across participants.

    Time frame: Monday, Wednesday, and Friday during Week 1 and Monday, Wednesday, and Friday during Week 2

  4. Proportion of Urine Samples Positive for Leukocyte Esterase (≥1+) by Time Point and Collection Device

    Urinary leukocyte esterase will be assessed by standard urinalysis (dipstick). Each participant will provide urine samples on three separate days during each of two weeks, with samples collected using both a standard urine cup and a Colli-Pee device. Leukocyte esterase results will be dichotomized as positive (≥1+) or negative. The outcome is the proportion of urine samples with a positive leukocyte esterase result at each collection visit for each collection device.

    Time frame: Monday, Wednesday, and Friday during Week 1 and Monday, Wednesday, and Friday during Week 2

  5. Detection of White Blood Cells Over Time

    Participants will provide urine samples on three days during each week of participation, for a total of 2 weeks. Urine samples collected in standard of care urine cups and Colli-Pee devices will be compared for white blood cells (WBC) per microliter, as detected by the Sysmex UP-5000. The UF5000 results will be the continuous variable of "WBCs per microliter" of urine. Specimens will be compared at 0 hours, 1 hour, 2 hours, 4 hours and 8 hours.

    Time frame: Monday, Wednesday, and Friday during Week 1 and Monday, Wednesday, and Friday during Week 2

  6. Detection of Leukocyte Esterase (LE) Over Time

    Participants will provide urine samples on three days during each week of participation, for a total of 2 weeks. Urine samples collected in standard of care urine cups and Colli-Pee devices will be compared for leukocyte esterase as detected by urinalysis. For the urinalysis, the categorical results will be "neg", "1+", "2+", "3+", and "4+" leukocyte esterase. Specimens will be compared at 0 hours, 1 hour, 2 hours, 4 hours and 8 hours.

    Time frame: Monday, Wednesday, and Friday during Week 1 and Monday, Wednesday, and Friday during Week 2

07

Results

Posted Aug 17, 2026

Participant flow

Participant flow — Overall Study
MilestoneColli-Pee Collection Followed by Standard-of-care Urine Collection CupStandard-of-care Urine Collection Followed by Colli-Pee Collection
Started911
Completed911
Not completed00

Outcome measures

PrimaryMedian Urinary White Blood Cell Count (WBCs/uL) by Collection Device (Urine Cup vs Colli-Pee)

Urinary white blood cell (WBC) counts (cells/µL) will be measured using a Sysmex UF-5000 urine flow cytometer. Each participant will provide urine samples on three separate days during each of two weeks, with samples collected using both a standard urine cup and a Colli-Pee device. WBC counts will be summarized using the median (and interquartile range) and compared between collection methods.

Time frame:
Monday, Wednesday, and Friday during Week 1 and Monday, Wednesday, and Friday during Week 2
Reported as:
Median · WBCs/ul urine
Median Urinary White Blood Cell Count (WBCs/uL) by Collection Device (Urine Cup vs Colli-Pee)
WBCs/ul urineUrine Cup Collection of UrineColli-Pee Collection of Urine
Median Urinary White Blood Cell Count (WBCs/uL) by Collection Device (Urine Cup vs Colli-Pee)1.800 (0.858 to 3.550)3.950 (2.117 to 7.450)
PrimaryProportion of Urine Samples Positive for Leukocyte Esterase (≥1+) by Collection Device (Urine Cup vs Colli-Pee)

Urinary leukocyte esterase will be assessed by standard urinalysis (dipstick). Each participant will provide urine samples on three separate days during each of two weeks, with samples collected using both a standard urine cup and a Colli-Pee device. Leukocyte esterase results will be recorded as an ordinal categorical variable with levels: negative, 1+, 2+, 3+, and 4+, and compared between collection methods.

Time frame:
Monday, Wednesday, and Friday during Week 1 and Monday, Wednesday, and Friday during Week 2
Reported as:
Count of units · urine samples
Proportion of Urine Samples Positive for Leukocyte Esterase (≥1+) by Collection Device (Urine Cup vs Colli-Pee)
urine samplesUrine Cup CollectionColli-Pee Collection
Proportion of Urine Samples Positive for Leukocyte Esterase (≥1+) by Collection Device (Urine Cup vs Colli-Pee)00
PrimaryWithin-Subject Coefficient of Variation of Urinary White Blood Cell Counts by Collection Device

Participants will provide urine samples on three days during each week of participation, for a total of 2 weeks. Urine samples collected in standard-of-care urine cups and Colli-Pee devices will be compared for white blood cell (WBC) concentration (WBCs/µL), as measured by the Sysmex UF-5000. Day-to-day variability will be quantified as the within-subject coefficient of variation (CV%) across the three sample collections for each collection method. Results are summarized as the median (interquartile range) CV% across participants.

Time frame:
Monday, Wednesday, and Friday during Week 1 and Monday, Wednesday, and Friday during Week 2
Reported as:
Median · Coefficient of variation
Within-Subject Coefficient of Variation of Urinary White Blood Cell Counts by Collection Device
Coefficient of variationUrine Collected With Urine CupUrine Collected With Colli-Pee
Within-Subject Coefficient of Variation of Urinary White Blood Cell Counts by Collection Device28.4 (24.2 to 51.0)38.4 (23.4 to 53.8)
PrimaryProportion of Urine Samples Positive for Leukocyte Esterase (≥1+) by Time Point and Collection Device

Urinary leukocyte esterase will be assessed by standard urinalysis (dipstick). Each participant will provide urine samples on three separate days during each of two weeks, with samples collected using both a standard urine cup and a Colli-Pee device. Leukocyte esterase results will be dichotomized as positive (≥1+) or negative. The outcome is the proportion of urine samples with a positive leukocyte esterase result at each collection visit for each collection device.

Time frame:
Monday, Wednesday, and Friday during Week 1 and Monday, Wednesday, and Friday during Week 2
Reported as:
Count of units · urine samples
Proportion of Urine Samples Positive for Leukocyte Esterase (≥1+) by Time Point and Collection Device
urine samplesUrine Cup Collection of UrineColli-Pee Collection of Urine
Time point 100
Time point 200
Time point 300
PrimaryDetection of White Blood Cells Over Time

Participants will provide urine samples on three days during each week of participation, for a total of 2 weeks. Urine samples collected in standard of care urine cups and Colli-Pee devices will be compared for white blood cells (WBC) per microliter, as detected by the Sysmex UP-5000. The UF5000 results will be the continuous variable of "WBCs per microliter" of urine. Specimens will be compared at 0 hours, 1 hour, 2 hours, 4 hours and 8 hours.

Time frame:
Monday, Wednesday, and Friday during Week 1 and Monday, Wednesday, and Friday during Week 2

No measurements were reported for this outcome.

PrimaryDetection of Leukocyte Esterase (LE) Over Time

Participants will provide urine samples on three days during each week of participation, for a total of 2 weeks. Urine samples collected in standard of care urine cups and Colli-Pee devices will be compared for leukocyte esterase as detected by urinalysis. For the urinalysis, the categorical results will be "neg", "1+", "2+", "3+", and "4+" leukocyte esterase. Specimens will be compared at 0 hours, 1 hour, 2 hours, 4 hours and 8 hours.

Time frame:
Monday, Wednesday, and Friday during Week 1 and Monday, Wednesday, and Friday during Week 2

No measurements were reported for this outcome.

Adverse events

Collected over No adverse event assessment performed. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Urine Cup Collection of Urine———
Colli-Pee Collection of Urine———

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Colli-Pee Collection Followed by Standard-of-care Urine Collection CupStandard-of-care Urine Collection Followed by Colli-Pee CollectionTotal
<=18 years000
Between 18 and 65 years91120
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Colli-Pee Collection Followed by Standard-of-care Urine Collection CupStandard-of-care Urine Collection Followed by Colli-Pee CollectionTotal
Female000
Male91120
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Colli-Pee Collection Followed by Standard-of-care Urine Collection CupStandard-of-care Urine Collection Followed by Colli-Pee CollectionTotal
Hispanic or Latino213
Not Hispanic or Latino71017
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Colli-Pee Collection Followed by Standard-of-care Urine Collection CupStandard-of-care Urine Collection Followed by Colli-Pee CollectionTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American011
White7714
More than one race123
Unknown or Not Reported000
08

Study locations

1 site
  • Indiana University
    Indianapolis, Indiana 46202, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Information and specimens collected for this study may be used for other research studies or shared with other researchers who are conducting their own research studies. This may include sharing with researchers outside Indiana University and sharing with private companies. It may also include making the information available in public and private databases of research data so that other researchers can use the information to answer research questions. If study staff share information or specimens in this way, they will remove information that could identify the subject(s), such as name and contact information, before any information or specimens are shared. Due to privacy concerns, IPD will not be shared.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in May 2025, 0 months.

Results were first posted in Aug 2026, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2025
First posted
Apr 30, 2025
StartActual
Apr 9, 2025
Primary completionActual
May 7, 2025
CompletionActual
May 7, 2025
Results first posted
Aug 17, 2026
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06951009
Lead sponsor
Indiana University
Responsible party
Stephen J. Jordan (Principal Investigator, Indiana University) — Principal investigator
First posted
Apr 30, 2025
Start date
Apr 9, 2025
Primary completion
May 7, 2025
Completion
May 7, 2025
Results posted
Aug 17, 2026
Last update
Aug 17, 2026

Study contacts

Stephen J Jordan, MD
principal investigator · Indiana University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion